Effects of metformin on early pregnancy loss in the polycystic ovary syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 2, 2002, Pages 524-529

  Jakubowicz, Daniela J ^a   Iuorno, Maria J ^b   Jakubowicz, Salomon ^c   Roberts, Katherine A ^c   Nestler, John E ^a,c  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b Hunter Holmes McGuire Vet Aff MC   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

ADULT; ARTICLE; DRUG EFFECT; FEMALE; FEMALE INFERTILITY; FIRST TRIMESTER PREGNANCY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SPONTANEOUS ABORTION;

FALLOPIA;

EID: 0036171653     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.2.8207     Document Type: Article

References (43)

1. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain
2. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study
3. Miscarriage rates following in vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin
4. Recurrent early miscarriage and polycystic ovaries
5. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome
6. Hypersecretion of luteinising hormone, infertility, and miscarriage
7. Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage
8. Subfertility and risk of spontaneous abortion
9. Influence of past reproductive performance on risk of spontaneous abortion
10. An informative protocol for the investigation of recurrent miscarriage: Preliminary experience of 500 consecutive cases
11. Recurrent miscarriage: Screening for polycystic ovaries and subsequent pregnancy outcome
12. Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial
13. Obesity is a risk factor for early pregnancy loss after IVF or ICSI
14. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function
15. Polycystic ovaries and levels of gonadotrophins and androgens in recurrent miscarriage: Prospective study in 50 women
16. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?
17. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome
18. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation
19. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome
20. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens
21. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction in insulin secretion in women with polycystic ovary syndrome
22. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome
23. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double-blind, placebo-controlled trial
24. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome
25. Ultrasound diagnosis of polycystic ovary syndrome
26. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
27. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: A pilot study
28. Administration of metformin to a diabetic woman with extreme hyperandrogenemia of nontumoral origin: Management of infertility and prevention of inadvertent masculinization of a female fetus
29. Therapeutic effects of metformin oninsulin resistance and hyperandrogenism in polycystic ovary syndrome
30. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome
31. Identification of placental protein 14 as an immunosuppressive factor in human reproduction
32. Suppression by human placental protein 14 of natural killer cell activity
33. Paracrine actions of insulin-like growth factors and IGF binding protein-1 in non-pregnant human endometrium and at the decidual-trophoblast interface
34. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence
35. The plasminogen activator system in women with polycystic ovary syndrome
36. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome
37. Plasminogen activator inhibitor activity: An independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome
38. Plasma fibrinolytic activators and their-inhibitors in women suffering from early recurrent abortion of unknown etiology
39. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome
40. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome
41. Metformin in management of pregnant insulin-independent diabetics
42. Oral hypoglycaemics in the first trimester and fetal outcome
43. The management of non-insulin-dependent diabetes during pregnancy